TLR9 and synovial sarcoma: To this end, administration of the oligonucleotide BL-7040, which activated TLR9 to induce an alternative NF-κB activation, in female NOD and TLR9-deficient mice led to amelioration of SS in NOD mice, including increased salivation and elevated anti-inflammatory responses in salivary glands, while TLR9-deficient mice were resistant to the salivation-promoting effect of BL-7040 (72).